SCHEMBL2169683

SCHEMBL2169683

CCOC(=O)CO/N=C\c1cc(Br)c(Oc2ccc(OC)c(Cc3ccccc3)c2)c(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.45
HPGD P15428 3/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 6/20 0.42
PKM P14618 1/20 0.42
POLB P06746 1/20 0.41
MAPT P10636 5/20 0.41
PRNP P04156 1/20 0.41
GAA P10253 1/20 0.41
ALOX12 P18054 1/20 0.41
ESR1 P03372 1/20 0.40
HTT P42858 2/20 0.40
APP P05067 1/20 0.38
GALR3 O60755 1/20 0.38
NR2F2 P24468 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2169685 1.00 LMNA (0.45) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL2170803 0.90 LMNA (0.43) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL2170800 0.90 LMNA (0.43) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL2169802 0.87 LMNA (0.41) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL16495653 0.87 LMNA (0.41) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL2170382 0.86 MAPT (0.40) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL16495869 0.86 LMNA (0.42) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL2187070 0.86 LMNA (0.42) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL16496687 0.85 MAPT (0.40) LMNAHPGDKMT2AKDM4EALDH1A1
SCHEMBL2170831 0.85 MAPT (0.40) LMNAHPGDKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US claimed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP claimed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO claimed
US-20110301200-A1 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2011-12-08 US disclosed
EP-2346814-A2 THYROID RECEPTOR LIGANDS Cadila Healthcare Limited (IN) 2011-07-27 EP disclosed
WO-2010049946-A2 THYROID RECEPTOR LIGANDS CADILA HEALTHCARE LIMITED (IN) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301200-A1 THYROID RECEPTOR LIGANDS TSHR, THRB, THRA LMNA 3227/4885HPGD 3201/4885KMT2A 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.